Eptinezumab: Long-Term Relief for Chronic Migraines in Japan

Research Summary

In the 60-week open-label SUNSET trial, published in J Headache Pain, researchers assessed the long-term tolerability and effectiveness of eptinezumab in Japanese adults suffering from chronic migraines. The study found that eptinezumab was generally well-tolerated over the extended period, with no new safety concerns arising. Participants experienced a significant reduction in monthly migraine days, showcasing eptinezumab's sustained effectiveness. This trial highlights eptinezumab as a promising option for Japanese patients, maintaining its beneficial effects over a long duration without compromising safety. These findings are crucial for clinicians managing chronic migraines, offering a reliable treatment alternative for long-term relief.

Study Details

📄 Title: Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial.

👥 Research Team: Takeshima T et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Nov 22

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.